Please assess the completion status of the following clinical trial:

Trial Title: TOFO Insulin Combination Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients aged 20-75 years old with type 2 diabetes mellitus (T2DM).~* Hemoglobin A1c ≥7.5% - ≤10.5% and FPG ≤220 mg/dL.~* Basal bolus (BB), Bolus, Premix, Basal supported oral therapy (BOT) regimens used for more than 12 weeks before screening.~* Stable dose (-/+20%) of insulin and no change in the dose of oral hypoglycemic agents for more than 12 weeks before screening.~* Only Dipeptidyl peptidase-4 inhibitor is allowed for basal supported oral therapy (BOT) regimen.~* Body mass index (BMI) ≥18.5 kg/m\^2 and \<35.0 kg/m\^2.~* No change of antihypertensive, anti-hypercholesterolemia and uric acid lowering drug 4 weeks before screening.~Exclusion criteria:~* Type 1 diabetes mellitus.~* Pregnancy or lactation.~* Severely uncontrolled glycemic situation.~* History of metabolic acidosis, including diabetic ketoacidosis, within 1 year prior to screening.~* History of myocardial infarction, stroke, or heart failure requiring hospitalization or drug or alcohol abuse within the previous 6 months.~* A measured serum creatinine level greater than 2.0 mg/dL for men and 1.5 mg/dL for women.~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2.5 times the upper limit of the reference range at the central laboratory test facility.~* Has previously received treatment with the investigational product.~* Has received treatment with another investigational product or non-approved drug within 3 months before tests for provisional enrolment.~* Corticosteroid therapy for 14 or more days in total within 8 weeks before tests for provisional enrolment (excluding those used for localized effects, such as drugs for topical \[skin\] application, eye drops and sprays).~* Patients who are frequently experiencing orthostatic hypotension.~* Required a change in the dosing regimen for the following drugs within 4 weeks before tests for provisional enrolment:~* Lipid-lowering drug~* Antihypertensive drug~* Thyroid hormone preparation~* Uric acid lowering drug~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- tofogliflozin (Type: EXPERIMENTAL): Tofogliflozin administered once daily for 52 weeks. Insulin administered as base treatment.
- placebo (Type: PLACEBO_COMPARATOR): Placebo administered once daily for 16 weeks. After 16-weeks, Tofogliflozin administered once daily for 36 weeks. Insulin administered as base treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).